Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia
Authors:
- 1 November 2007
- journal article
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 21 (8) , 837-842
Abstract
The object of this study is to assess 1) the relationship between plasma antipsychotic drug concentration, serum prolactin levels and the clinical efficacy of risperidone, 2) the relationship between the CYP2D6 polymorphisms and metabolizing of risperidone and 3) the role of 9-hydroxyrisperidone in elevating prolactin levels. One-hundred and eighteen Chinese schizophrenia patients (40 males, 78 females, age 15—60 years) were given risperidone at dosages ranging from 2—8 mg/day for 8 weeks. Clinical efficacy was determined using the Brief Psychiatric Rating Scores (BPRS). Serum prolactin levels were assayed before and after the 8 week treatment and plasma risperidone and 9-hydroxyrisperidone levels were also measured at the end of the 8-week treatment. The results showed there was no significant correlation between the concentration of active moiety and clinical response. Risperidone treatment significantly increased serum prolactin levels. Furthermore, changes of prolactin levels were not correlated with the clinical response. For the risperidone/ 9-hydroxyrisperidone ratio, there was a statistically significant difference among the CYP2D6*1/*1, *1/*10, *10/*10 genotypes (Kruskal—Wallis test, p = 0.012). No significant differences were found in the concentration of 9-hydroxyrisperidone and active moiety among the genotypes. In addition, the concentration of 9-hydroxyrisperidone was not significantly correlated with the increase of serum prolactin. In conclusion, our study has, for the first time, produced evidence that in Chinese schizophrenic patients, the metabolism of risperidone is dependent on CYP2D6. Neither changes in serum prolactin levels nor plasma concentration of active moiety were significantly correlated with clinical efficacy of risperidone. 9-hydroxyrisperidone may not play a predominant role in elevating serum prolactin level.Keywords
This publication has 29 references indexed in Scilit:
- The relationship between prolactin response and clinical efficacy of risperidone in acute psychotic inpatientsProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2006
- Predominant Role of the 9-Hydroxy Metabolite of Risperidone in Elevating Blood Prolactin LevelsAmerican Journal of Psychiatry, 2005
- Plasma Concentration of Risperidone Showed a Correlation with Daily Dose, but not with Age nor Cytochrome P‐450 2D6 Gene Polymorphisms in Japanese SchizophrenicsPsychogeriatrics, 2002
- Molecular Basis of Ethnic Differences in Drug Disposition and ResponseAnnual Review of Pharmacology and Toxicology, 2001
- Increased Dopamine D2 Receptor Occupancy and Elevated Prolactin Level Associated With Addition of Haloperidol to ClozapineAmerican Journal of Psychiatry, 2001
- The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophreniaClinical Therapeutics, 2000
- Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean populationPharmacogenetics, 1996
- Interpretation of a simple PCR analysis of the CYP2D6(A) and CYP2D6(B) null alleles associated with the debrisoquine/sparteine genetic polymorphismPharmacogenetics, 1994
- Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplificationThe Lancet, 1990
- Serum neuroleptic and prolactin levels in schizophrenic patients and clinical responsePsychiatry Research, 1983